HOME >> BIOLOGY >> NEWS
Study finds 60 new genes controlled by DNA snippet

the genetic code. Researchers also concluded that genes, specific batches of code that direct protein construction, comprise just about 2 percent of all human DNA. A central question in genetics has become: what does the remaining 98 percent of human genetic material do?

Regulatory sequences are emerging as an important part of the non-gene majority of human genetic material, once thought of as "junk DNA." A new frontier in genetic research is the defining of the regulome, the complete set of DNA sequences that regulate the behavior of genes. DNA segments that code for proteins average 200 base pairs in length, whereas regulatory sequences typically include just six to 10 base pairs, making them hard to find.

As a human embryo develops from a single cell into tens of billions of cells, DNA must be read and copied again and again to supply each cell with its needed copy. Over time, random changes, or mutations, are inserted into the code during the copying process. Some mutations bring survival advantages and others cause disease. Most known genetic diseases identified to date result from a mutation within a gene that directs protein construction, but that may soon change.

"We believe more and more disease-causing mutations will be found within regulatory sequences that control genes turning on or off," Miano said. "We therefore are very interested in defining as many functional regulatory elements as we can to help geneticists pinpoint a growing number of disease-causing mutations."

Study Details
In Miano's study, the regulatory sequence under examination was the CArG box. The nucleotide building blocks of DNA chains may contain any one of four nucleobases: adenine (A), thymine (T), guanine (G) and cytosine (C). Any sequence of code starting with 2 Cs, followed by any combination of 6 As or Ts, and ending in 2 Gs is a CArG box.

According to Miano, there are 1,216 variations of CArG box that together occur approx
'"/>

Contact: Greg Williams
Greg_Williams@urmc.rochester.edu
University of Rochester Medical Center
1-Feb-2006


Page: 1 2 3 4 5

Related biology news :

1. Study begins to reveal clues to the cause and progression of sepsis
2. Study finds gender differences in renal and other genes contributing to blood pressure
3. Study suggests estrogen deficiency can lead to obesity-induced high blood pressure after menopause
4. Study: Sticking to the sand might not be such good, clean fun for beachgoers
5. Study points to new way to predict death risk from torn aorta
6. Study identifies new gene therapy tools for inherited blindness
7. Study finds contaminated water reaching Floridas offshore keys
8. Study sheds light on why humans walk on two legs
9. Study explains how pathogens evolve to escape detection
10. Study finds hereditary link to premenstrual depression
11. Study identifies energy efficiency as reason for evolution of upright walking

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Study finds new genes controlled DNA snippet

(Date:7/8/2015)... DIEGO , July 8, 2015  Trovagene, ... cell-free molecular diagnostics, today announced the launch of ... the Company,s Precision Cancer Monitoring℠ (PCM) technology for ... receiving one or a combination of the novel ... Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient study ...
(Date:7/7/2015)... -- Research and Markets ( ... "Capacitive Fingerprint Sensors Patent Landscape" report ... fingerprint sensing technology is the most reliable and ... developed. This patent landscape focuses on fingerprint sensors ... of capacitive fingerprint sensors is closely linked to ...
(Date:7/7/2015)... 7, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... mobile commerce market announces a revised version of one of its ... will air on CNBC in New York , ... and San Francisco metro areas.    ... Wocket,s ability to replace all the cards in your wallet and ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
(Date:7/29/2015)... , ... July 29, 2015 , ... The third Medical ... combination products , in particular, drug/device combinations. The current system received a score ... Initiative for Patient Centered Innovation (iPCI) of Fairleigh Dickinson University’s ( FDU ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... it has selected an optimized Erk inhibitor molecule ... the development of a new class of potential ... represents a prime target for therapeutic intervention in ... and survival benefits for B-Raf and Mek inhibitors. ...
(Date:7/29/2015)... ... July 29, 2015 , ... CSSi ... Silicon Valley-based CRO specializing in Clinical Trial Management. CSSi LifeSciences is specialized in ... core expertise of PRC Clinical is focused on Clinical Trial Management, Clinical Site ...
(Date:7/29/2015)... TX (PRWEB) , ... July 29, 2015 , ... Costello ... new levee system to protect the Orange County, Texas area from future storm ... multi-firm design team in determining several potential levee alignment alternatives for providing protection, Costello ...
Breaking Biology Technology:Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3Preventing Storm Surge Flooding in Houston 2
Cached News: